.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Express Scripts
Teva
Farmers Insurance
Citi
Johnson and Johnson
Federal Trade Commission
Medtronic
Moodys
Cerilliant

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,056,890

« Back to Dashboard

Which drugs does patent 7,056,890 protect, and when does it expire?


Patent 7,056,890 protects QSYMIA and is included in one NDA. There has been one Paragraph IV challenge on Qsymia.

This patent has twenty-two patent family members in ten countries.

Summary for Patent: 7,056,890

Title:Combination therapy for effecting weight loss and treating obesity
Abstract: The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.
Inventor(s): Najarian; Thomas (Belmont, MA)
Assignee: VIVUS, Inc. (Mountain View, CA)
Application Number:10/454,368
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use; Delivery; Formulation; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
VivusQSYMIAphentermine hydrochloride; topiramateCAPSULE, EXTENDED RELEASE;ORAL022580-001Jul 17, 2012RXYesNo► Subscribe► Subscribe► SubscribeYUSE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
VivusQSYMIAphentermine hydrochloride; topiramateCAPSULE, EXTENDED RELEASE;ORAL022580-002Jul 17, 2012RXYesNo► Subscribe► Subscribe► SubscribeYUSE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
VivusQSYMIAphentermine hydrochloride; topiramateCAPSULE, EXTENDED RELEASE;ORAL022580-003Jul 17, 2012RXYesNo► Subscribe► Subscribe► SubscribeYUSE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
VivusQSYMIAphentermine hydrochloride; topiramateCAPSULE, EXTENDED RELEASE;ORAL022580-004Jul 17, 2012RXYesYes► Subscribe► Subscribe► SubscribeYUSE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,056,890

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,553,818Combination therapy for effecting weight loss and treating obesity► Subscribe
8,802,636Combination therapy for treatment of sleep apnea► Subscribe
7,674,776Combination therapy for effecting weight loss and treating obesity► Subscribe
7,659,256Combination therapy for effecting weight loss and treating obesity► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,056,890

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria369126► Subscribe
Australia2008262566► Subscribe
Australia5489600► Subscribe
Australia770068► Subscribe
Canada2377330► Subscribe
Canada2686633► Subscribe
Canada2692042► Subscribe
Cyprus1106974► Subscribe
Germany60035870► Subscribe
Denmark1187603► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Merck
Fish and Richardson
Teva
Farmers Insurance
Julphar
Johnson and Johnson
Chubb
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot